Although the utilization of immune checkpoint inhibitors (ICIs) such as antibodies against CTLA4 and PD-1/PD-L1 has revolutionized the treatment of melanoma in advanced stages, only a subset of patients shows long-lasting responses to this treatment. The gene discussed is PDCD1; the disease is melanoma.